NO133449B - - Google Patents
Download PDFInfo
- Publication number
- NO133449B NO133449B NO3184/71A NO318471A NO133449B NO 133449 B NO133449 B NO 133449B NO 3184/71 A NO3184/71 A NO 3184/71A NO 318471 A NO318471 A NO 318471A NO 133449 B NO133449 B NO 133449B
- Authority
- NO
- Norway
- Prior art keywords
- piperazinyl
- group
- phenthiazine
- propyl
- acid addition
- Prior art date
Links
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical class C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 11
- -1 cyano, methylthio, methanesulfonyl Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000004885 piperazines Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 125000005587 carbonate group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 26
- 239000000155 melt Substances 0.000 description 15
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 14
- 238000001953 recrystallisation Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Fremgangsmåte for fremstilling av terapeutisk aktive fentiazinderivater. Process for the preparation of therapeutically active phenthiazine derivatives.
Nærværende oppfinnelse angår en The present invention relates to a
fremgangsmåte for fremstilling av terapeutisk aktive fentiazinderivater. method for the preparation of therapeutically active phenthiazine derivatives.
Det er velkjent at forskjellige N-substituerte fentiazinderivater er i besiddelse It is well known that various N-substituted phenthiazine derivatives are in possession
av verdifulle terapeutiske egenskaper. Noen of valuable therapeutic properties. Some
er anvendelige først og fremst på grunn are applicable primarily due to
av deres fremragende antihistaminvirk-ning, andre på grunn av deres usedvanlig of their outstanding antihistamine effect, others because of their extraordinary
sterke effekt som potentiatorer for droger strong effect as potentiators for drugs
som virker på nervesystemet, og for deres which acts on the nervous system, and for their
effektivitet som antisjokkmidler og andre effectiveness as anti-shock agents and others
igjen er f. eks. effektive midler for å kon-trollere eller redusere bevegelsessyke. Ikke again is e.g. effective means to control or reduce motion sickness. Not
desto mindre er det blitt vist at av det the less it has been shown that of it
meget store antall mulige N-substituerte fentiazinforbindelser, som er blitt foreslått eller prøvet av forskjellige forskere, har bare forholdsvis få arter brukbar anven-delse i medisinen eller veterinærmedisinen, og at både naturen og graden av anvende-<]>ig effekt radikalt kan endres selv ved tilsynelatende små forandringer i kjemisk struktur. very large number of possible N-substituted phenthiazine compounds, which have been proposed or tested by various researchers, only relatively few species have useful use in medicine or veterinary medicine, and that both the nature and the degree of useful effect can be radically changed even with apparently small changes in chemical structure.
Det er en hensikt ved nærværende oppfinnelse å fremskaffe nye fentiazinderiva-<t>er, som har uventet anvendelige farma-kologiske egenskaper og som tilsvarer den generelle formel: i hvilken A betyr gruppen -(CHa)»- eller gruppen It is an aim of the present invention to provide new fenthiazine derivatives, which have unexpectedly applicable pharmacological properties and which correspond to the general formula: in which A means the group -(CHa)»- or the group
X betyr et hydro- X means a hydro-
gen- eller halogenatom eller en lavere al-kyl-, alkoksy- eller acylgruppe eller en gen or halogen atom or a lower alkyl, alkoxy or acyl group or a
cyano-, metyltio-, metansulfonyl, dimetylsulfamoyl- eller trifluormetylgruppe, og et cyano, methylthio, methanesulfonyl, dimethylsulfamoyl or trifluoromethyl group, and et
eller flere av carbonatomene i piperazin- or more of the carbon atoms in piperazine-
kjernen kan bære en lavere alkylgruppe, og deres sure addisjons- og kvaternære ammonumsalter. Uttrykket «lavere» når brukt i denne beskrivelse og etterfølgende påstander betyr, at den omhandlede grup- the nucleus may bear a lower alkyl group, and their acid addition and quaternary ammonium salts. The term "lower" when used in this description and subsequent claims means that the group in question
pe ikke innholder mere enn fire carbonat-atomer. pe does not contain more than four carbonate atoms.
Ifølge nærværende oppfinnelse frem-stilles fentiazinderivatene med generell formel I ved en fremgangsmåte som be-står i å omsette en forbindelse med formelen : According to the present invention, the phenthiazine derivatives of general formula I are prepared by a method which consists in reacting a compound with the formula:
med et piperazinylalkylfentiazin med den generelle formel: i hvilke et av symbolene P og Q betyr et hydrogenatom og det annet betyr gruppen -CO-Hal, og Hal betyr et halogenatom, A og X er som foran definert, og en eller flere av carbonatomene i piperazinkjernen kan bære en lavere alkylgruppe, eller et surt addisjonssalt av dette og, hvis ønsket, omdannelse av den slik oppnådde fentiazinbase til et surt addisjons- eller kvaternært ammoniumsalt. P er fortrinnsvis gruppen -CO-Hal, dvs. reaksjonsmidlet i formel II er et morfolinkarbonylhalogenid, og Q er et hydrogenatom. with a piperazinylalkylphenthiazine of the general formula: in which one of the symbols P and Q means a hydrogen atom and the other means the group -CO-Hal, and Hal means a halogen atom, A and X are as defined above, and one or more of the carbon atoms in the piperazine nucleus may carry a lower alkyl group, or an acid addition salt thereof and, if desired, conversion of the phenthiazine base thus obtained into an acid addition or quaternary ammonium salt. P is preferably the group -CO-Hal, i.e. the reactant in formula II is a morpholine carbonyl halide, and Q is a hydrogen atom.
Fremgangsmåten ifølge oppfinnelsen kan utføres ved oppvarmning av reaksjonskomponentene med eller uten et organisk oppløsningsmiddel. Det er fordelaktig å ar-beide i et aromatisk hydrocarbon- (f. eks. benzen) eller klorert alifatisk hydrocarbon (f. eks. kloroform) oppløsningsmiddel i nærvær av en organisk base, som f. eks. kan være et basisk reaksjonsmiddel eller pyridin, ved reaksjonsblandingens koke-temperatur. The method according to the invention can be carried out by heating the reaction components with or without an organic solvent. It is advantageous to work in an aromatic hydrocarbon (e.g. benzene) or chlorinated aliphatic hydrocarbon (e.g. chloroform) solvent in the presence of an organic base, such as e.g. can be a basic reactant or pyridine, at the boiling temperature of the reaction mixture.
Fentiazinderivatene oppnådd ved fremgangsmåten etter nærværende oppfinnelse er i besiddelse av interessante far-makodynamiske egenskaper. Særlig er de sterkt aktive neuroleptika med lav giftig-het, som har en sedativ virkning uten ka-taleptisk aktivitet. Av fremragende an-vendelighet som neuroleptika er 3-klor-10-[3 - (4-morf olinkarbonyl-l-piperazinyl) - propyl]fentiazin og 3-cyano-10-[3-(4-morfolinkarbonyl-l-piperazinyl)propyl]-fentiazin. The phenthiazine derivatives obtained by the method according to the present invention possess interesting pharmacodynamic properties. In particular, they are highly active neuroleptics with low toxicity, which have a sedative effect without cataleptic activity. Of outstanding utility as neuroleptics are 3-chloro-10-[3-(4-morpholinecarbonyl-1-piperazinyl)-propyl]phenthiazine and 3-cyano-10-[3-(4-morpholinecarbonyl-1-piperazinyl) propyl]-phenthiazine.
For terapeutiske formål anvendes ba-sene med generell formel I fortrinnsvis som sådanne eller i form av sure addi-sjonssalter, det vil si salter som inneholder anioner som er relativt harmløse overfor den animalske organisme i terapeutiske doser av saltene (som hydrokloridene, og andre hydrohalogenider, fosfater, nitrater, sulfater, acetater, suksinater, benzoater, maleater, fumarater teofyllinacetater, sa-licylater, fenolftalinater, eller metylen-bis-p-hydroksynaftoater) slik at basenes gun-stige fysiologiske egenskaper ikke påvirkes av bieffekter som kan tilskrives anionene. Likeledes kan de også brukes i form av kvaternære ammonumsalter oppnådd ved reaksjon med organiske halogenider (f.eks. metyl-, etyl-, jodid, -klorid eller -bromid, eller allyl- eller benzylklorid eller -bromid) eller andre reaksjonsdyktige estre, f. eks. sulfater og toluen-p-sulfonater. For therapeutic purposes, the bases of general formula I are preferably used as such or in the form of acid addition salts, i.e. salts containing anions which are relatively harmless to the animal organism in therapeutic doses of the salts (such as the hydrochlorides, and other hydrohalides , phosphates, nitrates, sulfates, acetates, succinates, benzoates, maleates, fumarates, theophylline acetates, salicylates, phenolphthalinates, or methylene-bis-p-hydroxynaphthoates) so that the beneficial physiological properties of the bases are not affected by side effects attributable to the anions. Likewise, they can also be used in the form of quaternary ammonium salts obtained by reaction with organic halides (e.g. methyl, ethyl, iodide, chloride or bromide, or allyl or benzyl chloride or bromide) or other reactive esters, e.g. e.g. sulfates and toluene p-sulfonates.
De følgende eksempler illustrerer oppfinnelsen. The following examples illustrate the invention.
Eksempel 1: Example 1:
Til en oppløsning av 3-klor-10[3-(l-piperazinyl)propyl]fentiazin (9 g) i benzen (35 cc.) tilsettes pyridin (2,1 g) fulgt av en oppløsning av morfolinkarbonylklorid (4 g) i benzen (15 cc). Etter oppvarming i 2 timer under tilbakeløp behandles blandingen med fortynnet natriumhydroksyd og ekstraheres med kloroform og kloro-formoppløsningen tørkes over kaliumkarbonat og konsentreres i vakuum. Der oppnåes 3-klor-10- [3- (4-morf olinkarbonyl-1 - piperazinyl)propyl]fentiazin (11 g), som smelter ved 148° C etter omkrystallisasjon fra etanol. To a solution of 3-chloro-10[3-(1-piperazinyl)propyl]phenthiazine (9 g) in benzene (35 cc.) is added pyridine (2.1 g), followed by a solution of morpholine carbonyl chloride (4 g) in benzene (15 cc). After heating for 2 hours under reflux, the mixture is treated with dilute sodium hydroxide and extracted with chloroform and the chloroform solution is dried over potassium carbonate and concentrated in vacuo. There is obtained 3-chloro-10-[3-(4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (11 g), which melts at 148° C after recrystallization from ethanol.
Eksempel 2: Example 2:
Ved å gå frem som i eksempel 1 men ved å begynne med 3-cyano-10[3-(l-piperazinyl)propyl]fentiazin (17,5) og morfolinkarbonylklorid (8 g) oppnåes der 3-cyano-10[3-4-morf olinkarbonyl-l-piperazinyl) propyl] fentiazin (17 g) som smelter ved 173° C etter omkrystallisasjon fra me-tanol. Proceeding as in Example 1 but starting with 3-cyano-10[3-(1-piperazinyl)propyl]phenthiazine (17.5) and morpholine carbonyl chloride (8 g) is obtained where 3-cyano-10[3- 4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (17 g) which melts at 173°C after recrystallization from methanol.
3-cyano-10- [3- (4-morf olinkarbonyl-l-piperazinyl)propyl]fentiazin (1,5 g) oppvarmes i 4 timer under tilbakeløp med me-tyljodid (8 cc.) og aceton (50 cc). Reak-sjonsblandingen tørres, oppløses i meta-nol og fortynnes med vannfri eter. Der oppnåes 3-cyano-10[3-(4-morfolinkarbo- 3-cyano-10-[3-(4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (1.5 g) is heated for 4 hours under reflux with methyl iodide (8 cc.) and acetone (50 cc). The reaction mixture is dried, dissolved in methanol and diluted with anhydrous ether. 3-cyano-10[3-(4-morpholinecarbo-
nyl-1 -piperazinyl) propyl] -f entiazinmet-jodid (1,6 g), som smelter ved ca. 150° C under spaltning. nyl-1-piperazinyl)propyl]-phenthiazinmeth iodide (1.6 g), which melts at ca. 150° C during decomposition.
Eksempel 3: 10 [ 3- (1 -piperazinyl) propyl] f entiazin (8 g) oppvarmes i kloroform (50 cc.) i 4 timer under tilbakeløp med vannfritt pyridin (2,2 g) og morfolinkarbonylklorid (4 Example 3: 10 [3-(1-piperazinyl)propyl]phenthiazin (8 g) is heated in chloroform (50 cc.) for 4 hours under reflux with anhydrous pyridine (2.2 g) and morpholine carbonyl chloride (4
g). Blandingen behandles derpå med en vannfri oppløsning av kaliumkarbonat og g). The mixture is then treated with an anhydrous solution of potassium carbonate and
kloroformoppløsningen konsentreres; resi-diet oppløses i en blanding av benzen og cykloheksan og kromatograferes over en alumininumoksydsøyle. Der oppnåes 10-[3-(4-morfolinkarbonyl-l-piperazinyl-propyl] f entiazin (10 g), som smelter ved 108° C etter omkrystallisasjon fra etylacetat. the chloroform solution is concentrated; the residue is dissolved in a mixture of benzene and cyclohexane and chromatographed over an alumina column. There is obtained 10-[3-(4-morpholinecarbonyl-1-piperazinyl-propyl]phenthiazine (10 g), which melts at 108° C. after recrystallization from ethyl acetate.
Eksempel 4: Example 4:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-klor-10-[3-(l-piperazinyl)-2-metylpropyl] f entiazin (9,4 g) og morfolinkarbonylklorid (3,6 g) oppnåes der 3-klor-10-[3-(4-morfolinkarbonyl-l-piperazinyl) -2-metylpropyl] f entiazin (10,2 g) hvis hydroklorid, krystallisert fra meta-nol, smelter ved 238—240° C. By proceeding as in Example 3 but starting with 3-chloro-10-[3-(1-piperazinyl)-2-methylpropyl] phentiazine (9.4 g) and morpholine carbonyl chloride (3.6 g), there is obtained 3-Chloro-10-[3-(4-morpholinecarbonyl-1-piperazinyl)-2-methylpropyl]phenthiazin (10.2 g) whose hydrochloride, crystallized from methanol, melts at 238-240°C.
Eksempel 5: Example 5:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-cyano-10-[3-(l-piperazinyl)-2-metylpropyl] f entiazin (9,1 g) og morfolinkarbonylklorid (4 g), oppnåes der 3-cyano-10- [3- (4-morf olinkarbonyl-1-piperazinyl)-2-metylpropyl]fentiazin (7 g), som smelter ved 160° C etter omkrystallisasjon fra etanol. Proceeding as in Example 3 but starting with 3-cyano-10-[3-(1-piperazinyl)-2-methylpropyl] phentiazine (9.1 g) and morpholine carbonyl chloride (4 g), there is obtained 3 -cyano-10-[3-(4-morpholinecarbonyl-1-piperazinyl)-2-methylpropyl]phenthiazine (7 g), which melts at 160° C. after recrystallization from ethanol.
Eksempel 6: Example 6:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-metoksy-10-[3-(l-piperazinyl) -2-metylpropyl] f entiazin (9,3 g) og morfolinkarbonylklorid (3,6 g) oppnåes der 3-metoksy-10-[3-(4-morfolinkarbonyl-1 -piperazinyl) -2-metylpropyl] f entiazin (9 g) hvis hydroklorid smelter ved 225—230° C etter omkrystallisasjon fra iso-propanol. By proceeding as in Example 3 but starting with 3-methoxy-10-[3-(1-piperazinyl)-2-methylpropyl]phenthiazin (9.3 g) and morpholine carbonyl chloride (3.6 g), there is obtained 3-Methoxy-10-[3-(4-morpholinecarbonyl-1-piperazinyl)-2-methylpropyl]phenthiazin (9 g) whose hydrochloride melts at 225-230° C. after recrystallization from iso-propanol.
Eksempel 7: Example 7:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-metoksy-10-[3-(l-piperazinyl) propyl] f entiazin (17,8 g) og morfolinkarbonylklorid (8,2 g) oppnåes der 3-metoksy-10-[3-(4-morf olinkarbonyl-1-piperazinyl)propyl]fentiazin (18 g) som smelter ved 119° C etter omkrystallisasjon fra etylacetat. Det tilsvarende sure maleat smelter ved 120—121° C etter omkrystallisasjon fra etylacetat. Proceeding as in Example 3 but starting with 3-methoxy-10-[3-(1-piperazinyl)propyl]phenthiazin (17.8 g) and morpholine carbonyl chloride (8.2 g) is obtained where 3-methoxy -10-[3-(4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (18 g) melting at 119° C. after recrystallization from ethyl acetate. The corresponding acidic maleate melts at 120-121° C after recrystallization from ethyl acetate.
Eksempel 8: Example 8:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-metyl-10-[l-piperazinyl)propyl]fentiazin (8,5 g) og morfolinkarbonylklorid (4 g) oppnåes der 3-metyl-10-[3-(4-morfolinkarbonyl-l-piperazinyl)-propyl]fentiazin (9,3 g) som smelter ved 110° C etter omkrystallisasjon fra aceton. Det tilsvarende sure maleat smelter ved 150° C etter omkrystallisasjon fra etylacetat. By proceeding as in Example 3 but starting with 3-methyl-10-[1-piperazinyl)propyl]phenthiazine (8.5 g) and morpholine carbonyl chloride (4 g), 3-methyl-10-[3- (4-morpholinecarbonyl-1-piperazinyl)-propyl]phenthiazine (9.3 g) melting at 110° C. after recrystallization from acetone. The corresponding acidic maleate melts at 150° C after recrystallization from ethyl acetate.
Eksempel 9: Example 9:
Ved å gå frem som i eksempel 3 men med å begynne med 3-trifluormetyl-10[3-(1-piperazinyl) propyl] f entiazin (7,8 g) og morfolinkarbonylklorid (3,3 g) oppnåes der 3-trifluormetyl-10-[3-(4-morf olinkarbonyl-l-piperazinyl)propyl]fentiazin (8,2 g) som smelter ved 100° C etter omkrystallisasjon fra petroleter (k.p. 70—120° C). By proceeding as in Example 3 but starting with 3-trifluoromethyl-10[3-(1-piperazinyl) propyl] phentiazine (7.8 g) and morpholine carbonyl chloride (3.3 g) is obtained where 3-trifluoromethyl- 10-[3-(4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (8.2 g) which melts at 100° C. after recrystallization from petroleum ether (b.p. 70-120° C.).
Eksempel 10: Example 10:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-metyltio-10-[3-(l-piperazinyl) propyl] f entiazin (7,4 g) og morfolinkarbonylklorid (3,3 g) oppnåes der 3-metyltio-10-[3-(4-morf olinkarbonyl-1-piperazinyl) propyl] f entiazin (8 g), hvis sure oksalat smelter ved 180° C etter omkrystallisasjon fra aceton. Proceeding as in Example 3 but starting with 3-methylthio-10-[3-(1-piperazinyl)propyl]phenthiazin (7.4 g) and morpholine carbonyl chloride (3.3 g) is obtained where 3-methylthio -10-[3-(4-morpholinecarbonyl-1-piperazinyl) propyl] phentiazine (8 g), whose acid oxalate melts at 180° C. after recrystallization from acetone.
Eksempel 11: Example 11:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-metansulfonyl-10-[3-(1-piperazinyl) propyl] f entiazin (4 g) og morfolinkarbonylklorid (1,6 g) oppnåes der 3-metansulfonyl-10-[3-(4-morf olinkarbonyl-l-piperazinyl)propyl]fentiazin (4,6 g) hvis sure oksalat smelter ved 174° C etter omkrystallisasjon fra aceton. Proceeding as in Example 3 but starting with 3-methanesulfonyl-10-[3-(1-piperazinyl)propyl]phenthiazin (4 g) and morpholine carbonyl chloride (1.6 g) is obtained where 3-methanesulfonyl-10 -[3-(4-morpholinecarbonyl-1-piperazinyl)propyl]phenthiazine (4.6 g) whose acid oxalate melts at 174° C. after recrystallization from acetone.
Eksempel 12: Example 12:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-dimetylsulfamoyl-10 By proceeding as in Example 3 but starting with 3-dimethylsulfamoyl-10
[3-(l-piperazinyl)propyl]fentiazin (9,6 g) [3-(1-piperazinyl)propyl]phenthiazine (9.6 g)
og morfolinkarbonylklorid (3,3 g) oppnåes der 3-dimetylsulfamoyl-10[3-(4-morfolinkarbonyl-1 -piperazinyl) propyl] f entiazin and morpholine carbonyl chloride (3.3 g) is obtained where 3-dimethylsulfamoyl-10[3-(4-morpholinecarbonyl-1-piperazinyl) propyl] phentiazine
(5,9 g), hvis sure oksalat smelter ved 185° C etter omkrystallisasjon fra aceton. (5.9 g), whose acid oxalate melts at 185° C. after recrystallization from acetone.
Eksempel 13: Example 13:
Ved å gå frem som i eksempel 3 men ved å begynne med 3-acetyl-10[3-(l-piperazinyl) propyl] f entiazin (7,5 g) og morfolinkarbonylklorid (3 g) oppnåes der 3-ace-tyl-10[3-(4-morf olinkarbonyl-l-piperazinyl)propyl] f entiazin (7 g) hvis sure oksalat, krystallisert fra aceton, smelter ved 189° C, blir fast igjen og smelter ved 206° C. By proceeding as in Example 3 but by starting with 3-acetyl-10[3-(1-piperazinyl)propyl]phenthazine (7.5 g) and morpholine carbonyl chloride (3 g) is obtained where 3-acetyl- 10[3-(4-morpholinecarbonyl-1-piperazinyl)propyl] phentiazine (7 g) whose acid oxalate, crystallized from acetone, melts at 189° C., solidifies again and melts at 206° C.
Eksempel 14: Example 14:
Ved å gå frem som i eksempel 3 men By proceeding as in example 3 but
ved å begynne med 3-metoksy-10-[3-(2,5-dimetyl-1 -piperazinyl) propyl] f entiazin starting with 3-methoxy-10-[3-(2,5-dimethyl-1-piperazinyl) propyl] phentiazine
(7,6 g) og morfolinkarbonylklorid (3,3 g) (7.6 g) and morpholine carbonyl chloride (3.3 g)
oppnåes der 3-metoksy-10-[3-(2,5-dimetyl-4- morfolinkarbonyl-1 -piperazinyl)propyl] - is obtained where 3-methoxy-10-[3-(2,5-dimethyl-4-morpholinecarbonyl-1-piperazinyl)propyl] -
fentiazin (4,9 g) i form av en harpiks. phenthiazine (4.9 g) in the form of a resin.
Eksempel 15: 3-klor-10-[3-(4-klorbarbonyl-l-piperazinyl) propyl] - f entiazinhydroklorid (2,1 Example 15: 3-chloro-10-[3-(4-chlorocarbonyl-1-piperazinyl)propyl]-phenthiazin hydrochloride (2,1
g) oppvarmes på vannbad med morfolin g) heated in a water bath with morpholine
(4,4 g). Etter behandling med natriumhydroksyd og kloroform oppnåes der 3-klor--10-[3-(4-morf olinkarbonyl-l-piperazi- (4.4g). After treatment with sodium hydroxide and chloroform, 3-chloro--10-[3-(4-morpholinecarbonyl-1-piperazi-
nyl)propyl]-fentiazin (2 g), identisk med produktet i eksempel 1. nyl)propyl]-phenthiazine (2 g), identical to the product in example 1.
3-klor-10-[3-(4-klorkarbonyl-l-(piperazinyl)ipropyl]-fentiazinhydroklorid (1,3 3-Chloro-10-[3-(4-chlorocarbonyl-1-(piperazinyl)ipropyl]-phenthiazine hydrochloride (1,3
g) oppnåes ved behandling av 3-klor-10-[3-(l-piperazinyl)propyl]fentiazin (14,4 g) g) is obtained by treating 3-chloro-10-[3-(1-piperazinyl)propyl]phenthiazine (14.4 g)
med en 20 %'s oppløsning (220 cc.) av fos-gen i toluen og pyridin (3,2 g) ved ca. 5— 10° C. Etter henstand over natten, filtreres det tungt oppløselige hydroklorid fra, vas-kes med vann og tørkes. with a 20% solution (220 cc.) of phosgene in toluene and pyridine (3.2 g) at approx. 5-10° C. After standing overnight, the poorly soluble hydrochloride is filtered off, washed with water and dried.
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3082871A GB1356379A (en) | 1970-08-27 | 1970-08-27 | Tetrazole derivatives |
GB3082871 | 1971-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO133449B true NO133449B (en) | 1976-01-26 |
NO133449C NO133449C (en) | 1976-05-05 |
Family
ID=26260624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO3184/71A NO133449C (en) | 1970-08-27 | 1971-08-26 |
Country Status (19)
Country | Link |
---|---|
AR (1) | AR193042A1 (en) |
AT (2) | AT319943B (en) |
AU (1) | AU3280571A (en) |
BE (1) | BE771818A (en) |
BG (1) | BG19182A3 (en) |
CH (5) | CH567017A5 (en) |
CU (1) | CU33570A (en) |
DD (1) | DD95008A5 (en) |
DE (1) | DE2142556A1 (en) |
ES (1) | ES394550A1 (en) |
FR (1) | FR2103553B1 (en) |
GB (1) | GB1356379A (en) |
HU (1) | HU164233B (en) |
IE (1) | IE35567B1 (en) |
IL (1) | IL37591A (en) |
LU (1) | LU63792A1 (en) |
NL (1) | NL7111790A (en) |
NO (1) | NO133449C (en) |
OA (1) | OA03910A (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1489749A (en) * | 1965-03-25 | 1967-07-28 | Fisons Pharmaceuticals Ltd | Process for the preparation of bis-chromonyl compounds and their derivatives |
CA960223A (en) * | 1970-02-05 | 1974-12-31 | Mervyn E. Peel | Tetrazolyl chromones |
-
1970
- 1970-08-27 GB GB3082871A patent/GB1356379A/en not_active Expired
-
1971
- 1971-08-24 OA OA54344A patent/OA03910A/en unknown
- 1971-08-25 BG BG19891A patent/BG19182A3/xx unknown
- 1971-08-25 CH CH732973A patent/CH567017A5/xx not_active IP Right Cessation
- 1971-08-25 CH CH1247871A patent/CH544108A/en not_active IP Right Cessation
- 1971-08-25 CH CH732773A patent/CH567016A5/xx unknown
- 1971-08-25 DE DE19712142556 patent/DE2142556A1/en active Pending
- 1971-08-25 HU HUFI492A patent/HU164233B/hu unknown
- 1971-08-25 CH CH732673A patent/CH567015A5/xx not_active IP Right Cessation
- 1971-08-25 CH CH733073A patent/CH544085A/en not_active IP Right Cessation
- 1971-08-26 NL NL7111790A patent/NL7111790A/xx unknown
- 1971-08-26 AT AT746471A patent/AT319943B/en not_active IP Right Cessation
- 1971-08-26 DD DD157355A patent/DD95008A5/xx unknown
- 1971-08-26 AR AR237589A patent/AR193042A1/en active
- 1971-08-26 FR FR7130935A patent/FR2103553B1/fr not_active Expired
- 1971-08-26 AT AT857573*1A patent/AT322553B/en not_active IP Right Cessation
- 1971-08-26 CU CU33570A patent/CU33570A/es unknown
- 1971-08-26 BE BE771818A patent/BE771818A/en unknown
- 1971-08-26 ES ES394550A patent/ES394550A1/en not_active Expired
- 1971-08-26 NO NO3184/71A patent/NO133449C/no unknown
- 1971-08-26 IE IE1073/71A patent/IE35567B1/en unknown
- 1971-08-26 AU AU32805/71A patent/AU3280571A/en not_active Expired
- 1971-08-26 IL IL37591A patent/IL37591A/en unknown
- 1971-08-26 LU LU63792D patent/LU63792A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AT322553B (en) | 1975-05-26 |
FR2103553B1 (en) | 1975-10-10 |
IE35567L (en) | 1972-02-27 |
CH567017A5 (en) | 1975-09-30 |
OA03910A (en) | 1975-08-14 |
DD95008A5 (en) | 1973-01-12 |
AU3280571A (en) | 1973-03-01 |
AT319943B (en) | 1975-01-10 |
FR2103553A1 (en) | 1972-04-14 |
ES394550A1 (en) | 1975-03-16 |
NO133449C (en) | 1976-05-05 |
IE35567B1 (en) | 1976-03-18 |
LU63792A1 (en) | 1972-04-04 |
NL7111790A (en) | 1972-02-29 |
GB1356379A (en) | 1974-06-12 |
BG19182A3 (en) | 1975-04-30 |
BE771818A (en) | 1972-02-28 |
IL37591A0 (en) | 1971-11-29 |
AR193042A1 (en) | 1973-03-30 |
HU164233B (en) | 1974-01-28 |
CH544085A (en) | 1973-12-28 |
CH567016A5 (en) | 1975-09-30 |
IL37591A (en) | 1974-12-31 |
CH544108A (en) | 1973-11-15 |
DE2142556A1 (en) | 1972-03-02 |
CH567015A5 (en) | 1975-09-30 |
CU33570A (en) | 1974-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60129210T2 (en) | CYCLIC AMID DERIVATIVES | |
US5001130A (en) | Psychotropic heterobicycloalkylpiperazine derivatives | |
NO162965B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALFA- (2-OXO-2,4,5,6,7,7A-HEXSAHYDROTIENO- (3,2-C) -5-PYRIDYL) -PHENYL-ACETIC ACID DERIVATIVES. | |
PT1500657E (en) | Substituted pyrazoles as p38 kinase inhibitors | |
NO122814B (en) | ||
BR112019024376A2 (en) | compound of general formula (i), or pharmaceutically acceptable salts thereof, pharmaceutical composition and use of the compounds or pharmaceutically acceptable salts thereof | |
DE69011645T2 (en) | Cycloheptenopyridine derivatives, process for their preparation and antiulcer agents containing them. | |
US3960863A (en) | Pyrido[1,2-a]pyrimidinone derivatives | |
US4086353A (en) | Certain azolinylamino (azolidinylimino) indazoles | |
DE69012653T2 (en) | Heterocyclic triazine or triazolo compounds with serotonin 2 receptor antagonist activity. | |
US2979502A (en) | Phenthiazine derivatives | |
NO138072B (en) | BREDB} NDSSPIRALANTENNE. | |
EP0273176A2 (en) | Fused heterocyclic tetrahydroaminoquinolinols and related compounds, a process for their preparation and their use as medicaments | |
US3636041A (en) | 4 5-dihydro-7h-thieno(2 3-c)thiopyrans | |
DE68926320T2 (en) | Pyrazoloacridone derivatives with antitumor activity | |
NO133449B (en) | ||
NO130329B (en) | ||
US3325497A (en) | Cycloheptatrienylpiperazines | |
CS226901B1 (en) | Thiazoloisoquinoline derivatives | |
US3536715A (en) | 2-lower alkyl-5-(omega-(4-phenyl-1-piperazinyl) lower alkyl)-2h-tetrazoles | |
DE68907845T2 (en) | Bridged bicyclic 4- (4- (3-benzisothiazolyl) -1-piperazinyl) butylimides with antipsychotic activity. | |
US3822267A (en) | 1 substituted 4 piperazino cycloalkylthiazoles | |
US3130194A (en) | Phenthiazine derivatives | |
SE438857B (en) | SET TO MAKE CHROMON DERIVATIVES | |
US3479356A (en) | 5h - dibenzo (a,d)-cycloheptatriene 10 or 11-(1,2,3,6-tetrahydro-4-pyridyl) and derivatives thereof |